JP2015145364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015145364A5 JP2015145364A5 JP2015020091A JP2015020091A JP2015145364A5 JP 2015145364 A5 JP2015145364 A5 JP 2015145364A5 JP 2015020091 A JP2015020091 A JP 2015020091A JP 2015020091 A JP2015020091 A JP 2015020091A JP 2015145364 A5 JP2015145364 A5 JP 2015145364A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- cyclodextrins
- group
- composition
- mixtures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000858 Cyclodextrin Polymers 0.000 claims 141
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 103
- 239000000203 mixture Substances 0.000 claims 58
- 239000003814 drug Substances 0.000 claims 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 30
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 30
- 229940097362 cyclodextrins Drugs 0.000 claims 29
- 229940079593 drug Drugs 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 21
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical class OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims 20
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims 20
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 20
- 230000002209 hydrophobic effect Effects 0.000 claims 19
- 238000002347 injection Methods 0.000 claims 19
- 239000007924 injection Substances 0.000 claims 19
- -1 sulfoalkyl ether β-cyclodextrins Chemical class 0.000 claims 19
- 238000000034 method Methods 0.000 claims 18
- 239000000872 buffer Substances 0.000 claims 17
- 239000003755 preservative agent Substances 0.000 claims 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 14
- 230000002335 preservative effect Effects 0.000 claims 14
- 230000000844 anti-bacterial effect Effects 0.000 claims 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 12
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical class OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims 10
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 10
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical class [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 10
- 239000001116 FEMA 4028 Substances 0.000 claims 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical class OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 10
- 150000005215 alkyl ethers Chemical class 0.000 claims 10
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 10
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 10
- 125000000129 anionic group Chemical group 0.000 claims 10
- 229960000686 benzalkonium chloride Drugs 0.000 claims 10
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 10
- 229960001950 benzethonium chloride Drugs 0.000 claims 10
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 10
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 10
- 229960004853 betadex Drugs 0.000 claims 10
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 10
- 239000004327 boric acid Substances 0.000 claims 10
- 229960002645 boric acid Drugs 0.000 claims 10
- 125000002091 cationic group Chemical group 0.000 claims 10
- 229960002798 cetrimide Drugs 0.000 claims 10
- 229960002242 chlorocresol Drugs 0.000 claims 10
- 239000006184 cosolvent Substances 0.000 claims 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 10
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 10
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 10
- 235000011187 glycerol Nutrition 0.000 claims 10
- 229940074076 glycerol formal Drugs 0.000 claims 10
- 229960005323 phenoxyethanol Drugs 0.000 claims 10
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 10
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 9
- 229960003742 phenol Drugs 0.000 claims 9
- 229910019142 PO4 Inorganic materials 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 8
- 239000010452 phosphate Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 230000000845 anti-microbial effect Effects 0.000 claims 7
- 229960004830 cetylpyridinium Drugs 0.000 claims 7
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical class CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 claims 7
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 229930003836 cresol Natural products 0.000 claims 6
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 5
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 claims 4
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 4
- 229960003305 alfaxalone Drugs 0.000 claims 4
- 229960003184 carprofen Drugs 0.000 claims 4
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims 4
- 229960001929 meloxicam Drugs 0.000 claims 4
- 229960004134 propofol Drugs 0.000 claims 4
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 229960004926 chlorobutanol Drugs 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 2
- 125000003717 m-cresyl group Chemical group [H]C1=C([H])C(O*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- CLWAXFZCVYJLLM-UHFFFAOYSA-N 1-chlorohexadecane Chemical compound CCCCCCCCCCCCCCCCCl CLWAXFZCVYJLLM-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000000337 buffer salt Substances 0.000 claims 1
- 229940067596 butylparaben Drugs 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011904970A AU2011904970A0 (en) | 2011-11-29 | Pharmaceutical compositions | |
| AU2011904970 | 2011-11-29 | ||
| AU2012904962 | 2012-11-09 | ||
| AU2012904962A AU2012904962A0 (en) | 2012-11-09 | Pharmaceutical compositions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542644A Division JP5819005B2 (ja) | 2011-11-29 | 2012-11-27 | 薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015145364A JP2015145364A (ja) | 2015-08-13 |
| JP2015145364A5 true JP2015145364A5 (enExample) | 2016-01-07 |
| JP6095707B2 JP6095707B2 (ja) | 2017-03-15 |
Family
ID=48534526
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542644A Active JP5819005B2 (ja) | 2011-11-29 | 2012-11-27 | 薬学的組成物 |
| JP2015020091A Active JP6095707B2 (ja) | 2011-11-29 | 2015-02-04 | 薬学的組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542644A Active JP5819005B2 (ja) | 2011-11-29 | 2012-11-27 | 薬学的組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9492552B2 (enExample) |
| EP (2) | EP2785352B1 (enExample) |
| JP (2) | JP5819005B2 (enExample) |
| KR (1) | KR101922752B1 (enExample) |
| CN (2) | CN107261152B (enExample) |
| AR (1) | AR089004A1 (enExample) |
| AU (1) | AU2012268889B2 (enExample) |
| BR (1) | BR112014012985B1 (enExample) |
| CA (1) | CA2852716C (enExample) |
| DK (1) | DK2785352T3 (enExample) |
| ES (1) | ES2784629T3 (enExample) |
| HR (1) | HRP20200567T1 (enExample) |
| IL (1) | IL232860B (enExample) |
| IN (1) | IN2014KN01341A (enExample) |
| SG (2) | SG11201401597TA (enExample) |
| TW (1) | TWI552770B (enExample) |
| WO (1) | WO2013078500A1 (enExample) |
| ZA (1) | ZA201402895B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
| RS59734B1 (sr) | 2012-01-23 | 2020-02-28 | Sage Therapeutics Inc | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| JP6180241B2 (ja) * | 2013-08-29 | 2017-08-16 | 学校法人同志社 | シクロデキストリン誘導体及び医薬組成物 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| US10858453B2 (en) | 2015-04-01 | 2020-12-08 | International Dioxcide, Inc. | Stabilized composition for combined odor control and enhanced dewatering |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| MA45276A (fr) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| KR101718733B1 (ko) * | 2015-08-21 | 2017-03-22 | 국제약품 주식회사 | 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제 |
| NL2015865B1 (en) * | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
| GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
| HUE070065T2 (hu) * | 2017-05-10 | 2025-05-28 | Axsome Therapeutics Inc | Gyógyszerkészítmények, amelyek meloxikámot tartalmaznak |
| CN110215430A (zh) * | 2018-03-02 | 2019-09-10 | 刘力 | 新型可注射的硝酸甘油药物组合物 |
| JP7374501B2 (ja) * | 2018-05-11 | 2023-11-07 | 南京清普生物科技有限公司 | メロキシカム組成物、製剤及びその製造方法と応用 |
| KR102141826B1 (ko) * | 2018-10-05 | 2020-08-07 | 건국대학교 산학협력단 | 양이온성 베타 시클로덱스트린 올리고머를 이용한 외부 pH 자극 반응형 자가치유성 하이드로젤 |
| WO2020093256A1 (zh) * | 2018-11-07 | 2020-05-14 | 比卡生物科技（广州）有限公司 | 一种澄清丙泊酚注射液及其制备方法 |
| JP7455852B2 (ja) * | 2019-02-15 | 2024-03-26 | ソール インターナショナル ディベロップメント エルティーディー． | 注射可能なフェノール製剤およびその使用の方法 |
| EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
| US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| EP3766475A1 (en) | 2019-07-15 | 2021-01-20 | OP-Hygiene IP GmbH | Wipes |
| FR3117337B1 (fr) * | 2020-12-10 | 2023-04-28 | Centre Hospitalier Univ De Lille | Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable |
| CN115487138A (zh) * | 2021-06-18 | 2022-12-20 | 北京万全德众医药生物技术有限公司 | 别孕烯醇酮注射剂及其制备方法 |
| KR102848049B1 (ko) | 2022-02-14 | 2025-08-20 | 주식회사 아크 | 파라벤계 보존제의 안정성 증진용 조성물 및 이를 포함하는 보존제 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4728509A (en) | 1985-08-19 | 1988-03-01 | Takeda Chemical Industries, Ltd. | Aqueous liquid preparation |
| TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
| JPH06293638A (ja) * | 1993-04-06 | 1994-10-21 | Lion Corp | 安定なビタミンａ類点眼剤 |
| ZA962214B (en) * | 1995-04-10 | 1996-10-07 | Farmarc Nederland Bv | Pharmaceutical composition |
| JP3934705B2 (ja) * | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
| TW434023B (en) * | 1995-09-18 | 2001-05-16 | Novartis Ag | Preserved ophthalmic composition |
| EP1109581A1 (en) | 1998-09-02 | 2001-06-27 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
| AUPQ633900A0 (en) | 2000-03-20 | 2000-04-15 | Jurox Pty Ltd | Anaesthetic composition |
| IN187686B (enExample) * | 2000-06-21 | 2002-06-08 | Bharat Serums & Vaccines Ltd | |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| JP2003089632A (ja) * | 2001-09-17 | 2003-03-28 | Otsuka Pharmaceut Factory Inc | 注射用水性製剤 |
| DE60305438T2 (de) * | 2002-02-01 | 2006-12-21 | Shimoda Biotech (Pty.) Ltd., Mill Park | Lyophilisierte pharmazeutische zusammensetzung von propofol |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| US20040053895A1 (en) * | 2002-09-18 | 2004-03-18 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
| JP4275394B2 (ja) * | 2002-12-05 | 2009-06-10 | 株式会社大塚製薬工場 | 注射用シロスタゾール水性製剤 |
| PT1713504T (pt) * | 2004-01-30 | 2017-08-29 | Zoetis Services Llc | Conservantes antimicrobianos para obter uma formulação multidose utilizando beta-ciclodextrinas para formas galénicas líquidas |
| US6969706B1 (en) | 2004-05-12 | 2005-11-29 | Allergan, Inc. | Preserved pharmaceutical compositions comprising cyclodextrins |
| EP2767163A1 (en) | 2005-02-17 | 2014-08-20 | Abbott Laboratories | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
| WO2007062339A2 (en) | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Liquid formulations |
| MY188453A (en) | 2008-11-15 | 2021-12-09 | Melinta Subsidiary Corp | Antimicrobial compositions |
| DK2525798T3 (da) * | 2010-01-21 | 2017-11-20 | Drawbridge Pharmaceuticals Pty Ltd | Anæstetisk formulering |
-
2012
- 2012-11-27 SG SG11201401597TA patent/SG11201401597TA/en unknown
- 2012-11-27 AU AU2012268889A patent/AU2012268889B2/en active Active
- 2012-11-27 DK DK12853138.1T patent/DK2785352T3/da active
- 2012-11-27 HR HRP20200567TT patent/HRP20200567T1/hr unknown
- 2012-11-27 SG SG10201506273PA patent/SG10201506273PA/en unknown
- 2012-11-27 KR KR1020147010730A patent/KR101922752B1/ko active Active
- 2012-11-27 WO PCT/AU2012/001452 patent/WO2013078500A1/en not_active Ceased
- 2012-11-27 JP JP2014542644A patent/JP5819005B2/ja active Active
- 2012-11-27 CA CA2852716A patent/CA2852716C/en active Active
- 2012-11-27 EP EP12853138.1A patent/EP2785352B1/en active Active
- 2012-11-27 BR BR112014012985-1A patent/BR112014012985B1/pt active IP Right Grant
- 2012-11-27 EP EP18198778.5A patent/EP3446692A1/en not_active Withdrawn
- 2012-11-27 IN IN1341KON2014 patent/IN2014KN01341A/en unknown
- 2012-11-27 ES ES12853138T patent/ES2784629T3/es active Active
- 2012-11-27 CN CN201710259261.9A patent/CN107261152B/zh active Active
- 2012-11-27 CN CN201280058592.1A patent/CN103998046B/zh active Active
- 2012-11-27 US US14/361,677 patent/US9492552B2/en active Active
- 2012-11-28 AR ARP120104457A patent/AR089004A1/es not_active Application Discontinuation
- 2012-11-29 TW TW101144782A patent/TWI552770B/zh active
-
2014
- 2014-04-22 ZA ZA2014/02895A patent/ZA201402895B/en unknown
- 2014-05-28 IL IL23286014A patent/IL232860B/en active IP Right Grant
-
2015
- 2015-02-04 JP JP2015020091A patent/JP6095707B2/ja active Active
-
2016
- 2016-09-29 US US15/280,826 patent/US10188664B2/en active Active
-
2018
- 2018-12-18 US US16/224,433 patent/US12303519B2/en active Active
-
2023
- 2023-05-26 US US18/324,305 patent/US20230293550A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015145364A5 (enExample) | ||
| US20230293550A1 (en) | Injectable pharmaceutical compositions comprising a cyclodextrin, a hydrophobic drug, a co-solvent and a preservative | |
| JP5654498B2 (ja) | ベンダムスチン環状多糖組成物 | |
| JP6272475B2 (ja) | 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物 | |
| CA2522115A1 (en) | A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid | |
| CN101410123A (zh) | 低剂量的双氯芬酸和β－环糊精的制剂 | |
| RS62057B1 (sr) | Formulacija maropitanta | |
| AU2013273764B2 (en) | Pharmaceutical compositions | |
| US20120035233A1 (en) | Medicinal cream made using miconazole nitrate and chitosan and a process to make the same | |
| NZ706101B2 (en) | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug | |
| NZ624592B2 (en) | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |